COPD Trial, Recruiting (NCT05708443)

COPD Trial, Recruiting NCT05708443 Sponsor: Istituti Clinici Scientifici Maugeri SpA Condition: COPD

Printed from Voxsanity (voxsanity.com.au) — NCT05708443 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Copd

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with moderate-to-severe COPD (classified as GOLD class 2 or 3)
People whose lung function test results (specifically how much air can be forcefully exhaled in one second) fall between 30% and 70% of what would normally be expected for someone of their age and size
People who are able to walk and climb stairs on their own, without help from another person or a mobility aid
People whose condition is currently stable, shown by a blood acidity level (pH) above 7.35

Who may not be able to join:

People who need to use oxygen at home on a long-term basis due to ongoing breathing failure
People with serious conditions affecting the bones and joints, nervous system, or heart
People who have difficulties with memory, thinking, or understanding
People who have had a recent flare-up of their COPD within the last 15 days that required a change in their medication or treatment
People who have a lung condition other than COPD
People who are considered to be in the terminal stage of their illness

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michele Vitacca, MD, ICS Maugeri IRCCS, respiratory rehabilitation of the Institute of Lumezzane

Phone: 0039+030+8253

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05708443

Sponsor: Istituti Clinici Scientifici Maugeri SpA

Phase: Not Applicable

Status: Recruiting

Condition: COPD

Trial contact: 0039+030+8253

More information: https://clinicaltrials.gov/study/NCT05708443

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with moderate-to-severe COPD (classified as GOLD class 2 or 3)
People whose lung function test results (specifically how much air can be forcefully exhaled in one second) fall between 30% and 70% of what would normally be expected for someone of their age and size
People who are able to walk and climb stairs on their own, without help from another person or a mobility aid
People whose condition is currently stable, shown by a blood acidity level (pH) above 7.35

Who may not be able to join:

People who need to use oxygen at home on a long-term basis due to ongoing breathing failure
People with serious conditions affecting the bones and joints, nervous system, or heart
People who have difficulties with memory, thinking, or understanding
People who have had a recent flare-up of their COPD within the last 15 days that required a change in their medication or treatment
People who have a lung condition other than COPD
People who are considered to be in the terminal stage of their illness

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Istituti Clinici Scientifici Maugeri SpA

Registry

ClinicalTrials.gov

Start date

10 January 2023

Est. completion

28 February 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Change in ADLs (GLITTRE test)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov